Valeant   4Q Revenues: $2.3 billion (+10%) 4Q Earnings: $534.1 million (earnings were $125.0 million 4Q13) FY Revenues: $8.3 billion (+43%) FY Earnings: $ 912.2 million (loss of 863.6 million FY13) Comments: Dermatology sales were up 70% in the quarter to $424.7 million. Consumer sales were $141.4 million, up 6%. Ophthalmology Rx sales were $131.8 million, up 8%. Other/Generics sales were $452.9 million, up 28%. Restructuring, integration and other acquisition related costs were $47 million ...